Physician profile
David B Mendelson
NPI 1386643567
$2,121.65
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $833 · 2021: $1,152 · 2022: $35.33.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $939.70 | 2021 | |
| Optinose US, INC. | $928.47 | 2020-2022 | |
| Genzyme Corporation | $57.04 | 2020-2021 | |
| Lilly USA, LLC | $48.57 | 2019 | |
| Karl Storz Endoscopy-America | $48.23 | 2021 | |
| Smith+Nephew, INC. | $23.55 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $23.48 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $18.03 | 2019 | |
| Stryker Corporation | $17.36 | 2019 | |
| Allergan, INC. | $17.22 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mendelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.